Joseph G. Oliveto
CEO, President & Executive DirectorMr. Joseph G. Oliveto, also known as Joe, M.B.A. has been Chief Executive Officer and President of Milestone Pharmaceuticals Inc. March 2017 and had been its Director since July 2017. He serves as Executive Director of Milestone Pharmaceuticals Inc. Mr. Oliveto served as Chief Executive Officer of Galleon Pharmaceuticals, Inc. from July 4, 2015 to June 2016. He served as the Chief Executive Officer and President of Chelsea Therapeutics International Ltd. since January 22, 2014 until August 4, 2015 and led through the FDA’s approval of Northera™ for the treatment of neurogenic orthostatic hypotension and the subsequent sale of Chelsea to Lundbeck, Inc. Mr. Oliveto served as an Interim Chief Executive Officer and President of Chelsea Therapeutics International Ltd. from July 9, 2012 to January 22, 2014 and served as its Vice President of Operations from June 2008 to July 8, 2012. He was responsible for overseeing key areas of Chelsea Therapeutics International Ltd. 's day-to-day operations, providing leadership for project management, manufacturing and operational aspects of commercialization activity for Droxidopa. Mr. Oliveto joined Chelsea in 2008 following a two-year assignment as Executive in Residence at Pappas Ventures, a life sciences venture capital firm, where he advised three portfolio companies as a board observer, gaining valuable venture capital investment experience and closing two follow-on investments. Prior to Pappas Ventures, he served in a number of progressively senior positions across several operating areas over an 18 year career at Hoffmann-La Roche Inc. most recently as a Global Alliance Director for Roche’s partnering organization. During his tenure, he played an integral part in the success of multiple NDA approvals, development of comprehensive launch programs, including those for both Pegasys and CoPegus and closed multiple licensing transactions. Mr. Oliveto is a seasoned pharmaceutical executive with more than 25 years of experience in the areas of drug development, commercialization and manufacturing as well as business development, having served as Chief Executive Officer for both public and private companies. His previous experience at Roche spans the areas of clinical development, project management, manufacturing process improvement and global business. He served as a Director of Galleon Pharmaceuticals, Inc. since December 30, 2015. He served as a Director of Chelsea Therapeutics International Ltd. from January 22, 2014 to August 4, 2015. Mr. Oliveto obtained BA degree in Chemistry and his MBA degree from Rutgers University.
Positions
- Company NameMilestone Pharmaceuticals Inc.Stock CodeMISTPositionCEO, President & Executive DirectorColleagues
- RJRobert James WillsIndependent Chairman of the Board
- AHAmit HasijaCFO & Executive VP of Corporate Development
- DBDavid B. BharuchaChief Medical Officer
- PDPhilippe DouvilleFounder, Strategic Advisor & Member of Scientific Advisory Board
- JNJeffrey NelsonChief Operating Officer
- PTPhilip T. SagerChief Medical Advisor & Member of the Scientific Advisory Board
- MJMichael John TomsicekIndependent Non-Executive Director
